10 Top Women in Biotech 2012

Life Sciences Tools & DiagnosticsMedical DevicesBiotechnology / Pharmaceuticals

Source: Fierce Biotech (11/8/12)

"Too few female professionals rise to senior executive roles in the biopharma industry, making the accomplishments of these women all the more exceptional."

Dr. Lynn Seely of Medivation ($MDVN) is spearheading the team that took Xtandi, a likely blockbuster for prostate cancer patients, all the way through the clinic to a first approval. At 23andMe, Anne Wojcicki aims to "connect" patients with genetic information that can help them take control of their own health. And Dr. Michelle Dipp of OvaScience wants to revolutionize the treatment of female infertility.

FierceBiotech's "10 Top Women in Biotech" honorees this year are top innovators in life sciences. Too few female professionals rise to senior executive roles in the biopharma industry, making the accomplishments of these women all the more exceptional. . .View Full Article

Cleantech/Life Sciences Co. Advances Products in Q2/25
Source: Richard Ryan (08/04/2025)

BioLargo Inc. (BLGO:OTCQX) enters into several agreements, forms partnerships and receives third party product validation, noted an Oak Ridge Financial report.

Clean Tech Firm Making Important PFAS Breakthrough
Source: Streetwise Reports (07/29/2025)

Clean technology company BioLargo Inc. (BLGO:OTCQX) president and chief executive office shares a mid-year update on the company's achievements so far this year, along with insights into its future prospects through a letter to shareholders.

Cancer Drug Developer Finds Potent Hits With AI in British Columbia
Source: Streetwise Reports (07/25/2025)

Rakovina Therapeutics Inc. (RKV:TSX.V) taps machine learning to zero in on novel cancer therapies. Read more about the AI engine driving this high-stakes discovery.

Oncolytics Biotech Inc. (ONCY:NASDAQ; ONC:TSX) published survival data for the use of its immunotherapy pelareorep in pancreatic cancer, and these support the view that this indication should be primary, noted a Leede Financial Inc. report.

Biotech Firm Clears Major U.S. Trading Hurdle
Source: Streetwise Reports (07/18/2025)

Rakovina Therapeutics Inc. (RKV:TSX.V) just gained DTC eligibility, opening the door for faster U.S. trades and broader investor access. With AI-driven cancer drugs in development, analysts are taking notice. Read more to find out why.